EirGenix
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Taiwan · 201-500 Employees
View Company Info for Free
Overview
Headquarters
No. 101 Lane 169 Kangning Xizhi District...Phone Number
+886 277080123Website
www.eirgenix.comRevenue
$95.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About EirGenix
EirGenix has been providing CDMO services since its establishment in 2013. In less than 7 years, the company has seen its operating income grow to a record high of 400 million New Taiwan Dollars in 2019, with its gross profit also reaching a record high. This year, EirGenix will continue to undertake even more contracts entrusted to it by international biotech and pharmaceutical companies from all over the world, including Japan, the United States, MainlandChina, and Europe. In its pioneer years, EirGenix primarily served the local Taiwanese market, but quickly expanded its business outside Taiwan to become the international CDMO company it is today. Now with the announcement of PMDA's authorization for EirGenix to manufacture marketed drug substances in Japan, EirGenix further expands its offerings to a more robust service life cycle, from early-stage research and development up to commercial manufacturing of marketed products. EirGenix's greater one-stop CDMO service offerings are ceRead more
EirGenix Org Chart
IL
Executive Director
HC
Executive Director, Manufacturing Technology ...
BW
Senior Director, Process Science
SW
Director, Commercial Operation
CT
廠長
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is EirGenix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
EirGenix, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if EirGenix had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at EirGenix
Funding: Get notified immidiatlly once EirGenix has new funding data
Product Launch: Get notified when EirGenix launches new products
Check out if EirGenix is spiking on competitors!
Check if EirGenix has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on EirGenix recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
EirGenix is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
EirGenix is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about EirGenix.
EirGenix Tech Stack
A closer look at the technologies used by EirGenix
Most Recent Scoops
Event
Product Marketing, Events, Training, Sales, Logistics / Supply Chain, Pharmaceuticals, Clinical Operations, Field Marketing, Manufacturing Operations, Operations
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Event
Events
Event
EirGenix News & Media
HER2 Positive Breast Cancer Pipeline 2024 | Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx,
HER2 Positive Breast Cancer Pipeline DELHI, DELHI, INDIA, July 3, 2024 /EINPresswire.com/ -- DelveInsight’s, “HER2 Positive Breast Cancer Pipeline Insight 2024” report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 …EirGenix's Breast Cancer Biosimilar Receives Marketing Authorization by EC
TAIPEI, Nov. 23, 2023 /PRNewswire/ -- EirGenix Inc. (6589. TT) announced today that its trastuzumab biosimilar medicine (EG12014) which their commercial partner Sandoz plans to commercialise (150 mg, for intravenous use) had received a marketing authorization from the European Commission...EirGenix's Breast Cancer Biosimilar Receives Marketing Authorization by EC
TAIPEI, Nov. 22, 2023 /PRNewswire/ -- EirGenix Inc. (6589. TT) announced today that its trastuzumab biosimilar medicine (EG12014) which their commercial partner Sandoz plans to commercialise (150 mg, for intravenous use) had received a marketing authorization from the European Commission...EirGenix's Second Breast Cancer Biosimilar EG1206A Successfully Reaches Phase 1 Clinical Trial Objectives
TAIPEI, May 2, 2023 /PRNewswire/ -- EirGenix, Inc. (6589.TT) announced on 28th of April that it has completed the phase 1 clinical trial (EGC101) of its second breast cancer biosimilar EG1206A in Europe. Comparing EG1206A to Roch's Perjeta® US and EU, results of the clinical data analysis...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding EirGenix
Sign Up For FreeTo access detailed company insights
EirGenix has been providing CDMO services since its establishment in 2013. In less than 7 years, the company has seen its operating income grow to a record high of 400 million New Taiwan Dollars in 2019, with its gross profit also reaching a record high. This year, EirGenix will continue to undertake even more contracts entrusted to it by internati... Read More
